These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 36342974)

  • 1. A qualitative study of stakeholder and researcher perspectives of community engagement practices for HIV vaccine clinical trials in South Africa.
    Dietrich JJ; Munoz J; Tshabalala G; Makhale LM; Hornschuh S; Rentas F; Mulaudzi M; Laher F; Andrasik MP
    J Community Psychol; 2023 Apr; 51(3):998-1015. PubMed ID: 36342974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experiences from a community advisory Board in the Implementation of early access to ART for all in Eswatini: a qualitative study.
    Mlambo CK; Vernooij E; Geut R; Vrolings E; Shongwe B; Jiwan S; Fleming Y; Khumalo G
    BMC Med Ethics; 2019 Jul; 20(1):50. PubMed ID: 31311526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Participants' characteristics and motivations to screen for HIV vaccine and monoclonal antibody trials in KwaZulu-Natal, South Africa.
    Hanass-Hancock J; Carpenter B; Reddy T; Nzuza A; Gaffoor Z; Goga A; Andrasik M
    Trials; 2021 Dec; 22(1):897. PubMed ID: 34895272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring a community's understanding of HIV vaccine‑induced seropositivity in a South African research setting.
    Malahleha M; Dilraj A; Jean J; Morar NS; Dietrich JJ; Ross M; Mbatsane E; Keefer MC; Ahmed K
    S Afr Med J; 2022 Dec; 113(1):36-41. PubMed ID: 36537546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rules of engagement: perspectives on stakeholder engagement for genomic biobanking research in South Africa.
    Staunton C; Tindana P; Hendricks M; Moodley K
    BMC Med Ethics; 2018 Feb; 19(1):13. PubMed ID: 29482536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. "Why Don't You Go Into Suburbs? Why Are You Targeting Us?": Trust and Mistrust in HIV Vaccine Trials in South Africa.
    Thabethe S; Slack C; Lindegger G; Wilkinson A; Wassenaar D; Kerr P; Bekker LG; Mngadi K; Newman PA
    J Empir Res Hum Res Ethics; 2018 Dec; 13(5):525-536. PubMed ID: 30417754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Standardized metrics can reveal region-specific opportunities in community engagement to aid recruitment in HIV prevention trials.
    Broder GB; Lucas JP; Davis J; Wallace SE; Luthuli N; Baepanye K; White RR; Bolton M; Blanchette C; Andrasik MP
    PLoS One; 2020; 15(9):e0239276. PubMed ID: 32941520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of community advisory boards during conduct of clinical trials in Uganda: a qualitative study involving stakeholders.
    Mijumbi AO; Mugenyi L; Nanfuka M; Agaba C; Ochieng J
    BMC Health Serv Res; 2023 Feb; 23(1):119. PubMed ID: 36740683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV cure research in South Africa: a preliminary exploration of stakeholder perspectives.
    Moodley K; Staunton C; de Roubaix M; Cotton M
    AIDS Care; 2016; 28(4):524-7. PubMed ID: 26565595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Forming and implementing community advisory boards in low- and middle-income countries: a scoping review.
    Zhao Y; Fitzpatrick T; Wan B; Day S; Mathews A; Tucker JD
    BMC Med Ethics; 2019 Oct; 20(1):73. PubMed ID: 31623624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A mixed methods investigation of implementation barriers and facilitators to a daily mobile phone sexual risk assessment for young women in Soweto, South Africa.
    Dietrich JJ; Hornschuh S; Khunwane M; Makhale LM; Otwombe K; Morgan C; Huang Y; Lemos M; Lazarus E; Kublin JG; Gray GE; Laher F; Andrasik M;
    PLoS One; 2020; 15(4):e0231086. PubMed ID: 32324753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring researchers' experiences of working with a researcher-driven, population-specific community advisory board in a South African schizophrenia genomics study.
    Campbell MM; Susser E; de Vries J; Baldinger A; Sibeko G; Mndini MM; Mqulwana SG; Ntola OA; Ramesar RS; Stein DJ
    BMC Med Ethics; 2015 Jul; 16():45. PubMed ID: 26135122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Towards a Science of Community Stakeholder Engagement in Biomedical HIV Prevention Trials: An Embedded Four-Country Case Study.
    Newman PA; Rubincam C; Slack C; Essack Z; Chakrapani V; Chuang DM; Tepjan S; Shunmugam M; Roungprakhon S; Logie C; Koen J; Lindegger G
    PLoS One; 2015; 10(8):e0135937. PubMed ID: 26295159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Caveats and pitfalls associated with researching community engagement in the context of HIV vaccine trials.
    Kagee A; De Wet A; Kafaar Z; Lesch A; Swartz L; Newman PA
    J Health Psychol; 2020 Jan; 25(1):82-91. PubMed ID: 29243520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 'It looks like you just want them when things get rough': civil society perspectives on negative trial results and stakeholder engagement in HIV prevention trials.
    Koen J; Essack Z; Slack C; Lindegger G; Newman PA
    Dev World Bioeth; 2013 Dec; 13(3):138-48. PubMed ID: 22998395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of community advisory boards in health research: Divergent views in the South African experience.
    Reddy P; Buchanan D; Sifunda S; James S; Naidoo N
    SAHARA J; 2010 Oct; 7(3):2-8. PubMed ID: 21409299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Civil society perspectives on negative biomedical HIV prevention trial results and implications for future trials.
    Essack Z; Koen J; Slack C; Lindegger G; Newman PA
    AIDS Care; 2012; 24(10):1249-54. PubMed ID: 22360605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Willingness to use HIV prevention methods among vaccine efficacy trial participants in Soweto, South Africa: discretion is important.
    Laher F; Salami T; Hornschuh S; Makhale LM; Khunwane M; Andrasik MP; Gray GE; Van Tieu H; Dietrich JJ
    BMC Public Health; 2020 Nov; 20(1):1669. PubMed ID: 33160341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Who to engage in HIV vaccine trial benefit-sharing negotiations? An empirical proposition of a framework.
    Pancras G; Ezekiel M; Mbugi E; Merz JF
    BMC Med Ethics; 2024 May; 25(1):54. PubMed ID: 38745276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial.
    Bekker LG; Moodie Z; Grunenberg N; Laher F; Tomaras GD; Cohen KW; Allen M; Malahleha M; Mngadi K; Daniels B; Innes C; Bentley C; Frahm N; Morris DE; Morris L; Mkhize NN; Montefiori DC; Sarzotti-Kelsoe M; Grant S; Yu C; Mehra VL; Pensiero MN; Phogat S; DiazGranados CA; Barnett SW; Kanesa-Thasan N; Koutsoukos M; Michael NL; Robb ML; Kublin JG; Gilbert PB; Corey L; Gray GE; McElrath MJ;
    Lancet HIV; 2018 Jul; 5(7):e366-e378. PubMed ID: 29898870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.